Phenomenex has announced the publication of a case study, written by scientists at Pfizer, that demonstrates the results of a new method for residual API (active pharmaceutical ingredient) analysis.
The method requires one UHPLC instrument, using Phenomenex Kinetex 1.7-micron core-shell columns, to resolve all 16 ingredients in six minutes.
In addition to instrument and time savings, the method uses less solvent, reduces waste-disposal costs and frees up lab analysts.
The Kinetex 1.7-micron column typically delivers efficiency gains of 15 to 20 per cent over traditional fully porous sub-2-micron columns, according to the company.
